Contribute Try STAT+ Today

An experimental medicine appeared to slow the decline of patients with the early symptoms of Alzheimer’s disease, the drug’s maker, Eli Lilly, said.

The results are likely to generate both excitement and debate in the Alzheimer’s field, because the study is small — enrolling just 272 patients — and because the medicine, donanemab, is the latest in a line of similar drugs that all target the same basic chemical mechanism, known as beta amyloid. Multiple previous beta amyloid-targeting drugs have failed to reach the market, costing drugmakers billions of dollars in wasted research dollars. In November, a panel of expert advisers to the Food and Drug Administration voted that the latest, aducanumab from Biogen, should not be approved. The FDA has not reached a decision on aducanumab, but usually follows the advice of its expert panels. Lilly’s results may be enough to bring debate about the “amyloid hypothesis,” which had settled down, back to life.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.